We thank Chu and colleagues ([10][1]) for highlighting the potential impact of the 2019 revised Clinical and Laboratory Standards Institute (CLSI) Enterobacteriaceae fluoroquinolone breakpoints on the reporting of other members… Click to show full abstract
We thank Chu and colleagues ([10][1]) for highlighting the potential impact of the 2019 revised Clinical and Laboratory Standards Institute (CLSI) Enterobacteriaceae fluoroquinolone breakpoints on the reporting of other members of this antibiotic class, in this case, nalidixic acid. As noted by the
Keywords:
clsi;
reply chu;
fluoroquinolone breakpoints;
chu adoption;
adoption new
Journal Title: Journal of Clinical Microbiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Microbiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!